CGEN Compugen Limited: Enterprise Value-to-Revenue Multiple

Public company logo of Compugen Ltd (CGEN)

The EV/Sales trajectory for Compugen Ltd. (CGEN) on GURU.Markets correlates with moderate capacity utilization of antibody synthesis laboratories, while 934.15 reflects the latest metric value. A high barrier to entry is ensured by the patent portfolio and strict FDA oversight. Compugen Ltd. (CGEN) is also developing a science and technology hub, combining AI-driven target discovery with biology to create unique methods for combating tumors.

Company Value to Revenue: Compugen Limited (CGEN) for 11/23/2025 - 11/19/2026

Compugen Limited - analytical breakdowns and key metrics (CGEN)

- share price and consensus valuation forecast:
Initial company analysis:Compugen Ltd CGEN
Product sample of Compugen Ltd

The stable IP monetization strategy led by Anat Cohen-Dayag is reflected in the shift of the EV/Sales ratio for Compugen Ltd. (CGEN). This metric compares the total enterprise value of the business with annual revenue, excluding the impact of leverage. The calculation combines market capitalization and net debt, divided by revenue. Low values signal either undervaluation or a systemic crisis in the model. This tool allows for the identification of institutional accumulation phases of the asset.

Competitor analysis for Compugen Ltd.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP